Head and Neck Cancer Trial, Recruiting NCT05793151 Sponsor: Medical University of South Carolina Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT05793151
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People diagnosed with a type of cancer called squamous cell carcinoma (or a closely related type) affecting the mouth, throat, voice box, nasal area, or sinuses — or where the original source of the cancer is unknown
  • People whose cancer has been assessed as moderately to severely advanced in size or spread, based on a standard cancer staging system (called AJCC 8th edition)
  • People who have not previously had radiation therapy for this type of head and neck cancer in a way that would, in the treating doctor's judgement, affect the need for radiation after surgery
  • People who are already planned to have surgery with the goal of curing the cancer at one of the participating hospitals
  • People for whom the treating team expects to recommend radiation therapy after surgery — with or without chemotherapy — based on the likelihood of finding at least one of the following in the surgical specimen: advanced tumour stage (pT3 or pT4), cancer spread to lymph nodes, cancer growing along nerves, or cancer found in blood or lymph vessels

Who may not be able to join:

  • People who are not able to speak or read English or Spanish
  • People living with severe mental illness that would prevent participation in the trial
  • People whose cancer is HPV-positive, located in the oropharynx or of unknown origin, and is at an earlier stage with only a single lymph node involved that is smaller than 3 cm on the same side as the tumour
  • People who have another separate, untreated cancer at the same time that is expected to affect how long they are likely to live

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Evan M Graboyes, MD, MPH, Medical University of South Carolina

Phone: 843-792-0719

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
30 October 2023
Est. completion
30 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Initiation of Timely PORT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov